Pertussis: Is eradication achievable?

Pediatric Annals

Volumn 33, Issue 8, 2004, Pages 524-534

  Steele, Russell W ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; ADENYLATE CYCLASE TOXIN; AZITHROMYCIN; BOOSTRIX TDAP; CLARITHROMYCIN; CYTOTOXIN; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; ERYTHROMYCIN; HEAT LABILE TOXIN; HEMAGGLUTININ; LIPOOLIGOSACCHARIDE; PERTACTIN; PERTUSSIS TOXIN; TOXIN ANTIBODY; TRACHEAL CYTOTOXIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR; PERTUSSIS VACCINE;

ANAPHYLAXIS; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BACTERIUM CULTURE; BORDETELLA PERTUSSIS; BRAIN DISEASE; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; EDEMA; EPIDEMIC; EPIDEMIOLOGICAL DATA; ERADICATION THERAPY; ERYTHEMA; FATALITY; FEVER; FIMBRIA; HARDNESS; HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; HYPERTROPHIC PYLORUS STENOSIS; IMMUNIZATION; IRRITABILITY; LETHARGY; MOOD DISORDER; NONHUMAN; NUTRITIONAL SUPPORT; PAIN; PERTUSSIS; PNEUMONIA; PROGNOSIS; REVIEW; SIDE EFFECT; SOMNOLENCE; VACCINATION; ARTICLE; INFANT; INFANT WELFARE; ISOLATION AND PURIFICATION; MICROBIOLOGY; NASOPHARYNX; WORLD HEALTH ORGANIZATION;

BORDETELLA PERTUSSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT WELFARE; NASOPHARYNX; PERTUSSIS VACCINE; WHOOPING COUGH; WORLD HEALTH ORGANIZATION;

EID: 16544370728     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-20040801-10     Document Type: Review

References (50)

1. Steele RW. Acellular pertussis vaccine: a major step towards disease eradication. Infect Med. 1996;13(Suppl E):11-65.
2. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815-820.
3. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-7):1-25.
4. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003;22(7):628-634.
5. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis. 1999;29(Suppl 2):S112-S117.
6. Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis. 2004;38(4):591-594.
7. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815-820.
8. Cone TE Jr. Whooping cough is first described as a disease in sui generis by Ballou in 1640. Pediatrics. 1970;46:522.
9. Resurgence of pertussis - United States 1993. MMWR Morb Mortal Wkly Rep. 1993;42(49):952-953, 959-960.
10. Woolfrey BF, Moody JA. Human infections associated with Bordetella bronchiseptica. Clin Microbiol Rev. 1991;4(3):243-255.
11. Cherry JD, Brunell PA, Golden GS, et al. Report of the task force on pertussis and pertussis immunization - 1988. Pediatrics. 1988;81(Suppl):939-984.
12. Bass JW, Klenk EL, Kotheimer JB, Linnemann CC, Smith MH. Antimicrobial treatment of pertussis. J Pediatr. 1969;75(5):768-781.
13. Medical Economics Staff. Physicians' Desk Reference. 57th ed. Washington, DC: Thomson Healthcare; 2003.
14. Pertussis - United States, 1997-2000. MMWR Morb Mortal Wkly Rep. 2002;51(4):73-76.
15. Cherry JD. Viewpoint on pertussis. Pediatric Vaccine Reporter. 1998;2:6-7.
16. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16(20):1901-1906.
17. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996;334(6):349-355.
18. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccities. Lancet. 1997;350(9091):1569-1577.
19. Edwards KM, Decker MD. Comparison of serological results in the NIAID Multicenter Acellular Pertussis Trial with recent efficacy trials. Dev Biol Stand. 1997;89:265-273.
20. American Academy of Pediatrics. Pertussis. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Evanston, IL: American Academy of Pediatrics: 2004:476.
21. Robinson A, Irons LI, Seabrook RN, et al. Structure-function studies of Bordetella pertussis fimbriae. In: Manclark CR, ed. Proceedings of the Sixth International Symposium on Pertussis. Bethesda, MD: Bethesda Dept of Health and Human Services, United States Public Health Service; 1990:126-135.
22. Hellwig SM, Rodriguez ME, Berbers GA, van de Winkel JG, Mooi FR. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis. 2003;188(5):738-742.
23. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16(20):1907-1916.
24. Mills KH, Redhead K. Cellular immunity in pertussis. J Med Microbiol. 1993;39(3):163-164.
25. Robinson A, Ashworth LA, Irons LI. Serotyping Bordetella pertussis strains. Vaccine. 1989;7(6):491-494.
26. Cherry JD, Xing DX, Newland P, et al. Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin Infect Dis. 2004;38(4):502-507.
27. Hewlett EL, Gordon VM. Adenylate cyclase toxin of Bordetella pertussis. In: Wardlaw AC, Parton R, eds. Pathogenesis and Immunity in Pertussis. New York, NY: John Wiley & Sons; 1988:193-209.
28. Bordet J, Gengou O. L'endotoxin coquelucheuse. Ann Inst Pasteur. 1909;23:415-419.
29. Nakase Y, Endoh M. Heat-labile toxin of Bordetella pertussis. In: Wardlaw AC, Parton R, eds. Pathogenesis and immunity in pertussis. New York, NY: John Wiley & Sons; 1988;217-229.
30. Chaby R, Caroff M. Lipopolysaccarides of Bordetella pertussis endotoxin. In: Wardlaw AC, Parton R, eds. Pathogenesis and Immunity in Pertussis. New York, NY: John Wiley & Sons; 1988:247-272.
31. Mountzouros KT, Kimura A, Cowel JL. A bactericial monoclonal antibody specific for the lipooligosaccaride of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis. Infect Immun. 1992;60:5316-5318.
32. Cundell DR, Kanthakumar K, Taylor GW, et al. Effect of tracheal cytotoxin from Bordetella pertussis on human neutrophil function in vitro. Infect Immun. 1994;62(2):639-643.
33. Goldman WE. Tracheal cytotoxin of Bordetella pertussis. In: Wardlaw AC, Parton R, eds. Pathogenesis and Immunity in Pertussis. New York, NY: John Wily & Sons; 1988:237-246.
34. Sato H, Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun. 1984;46(2):415-421.
35. Shahin RD, Amsbaugh DF, Leef MF. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection. Infect Immun. 1992;60(4):1482-1488.
36. Charles IG, Li JL, Roberts M, et al. Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis. Eur J Immunol. 1991;21(5):1147-1153.
37. Shahin RD, Brennan MJ, Li ZM, Meade BD, Manclark CR. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med. 1990;171(1):63-73.
38. Jones DH, McBride BW, Jeffery H, et al. Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae. Vaccine. 1995;13(7):675-681.
39. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med. 1996;334(6):341-348.
40. Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275(1):37-41.
41. Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med. 1995;333(16):1045-1050.
42. Acellular pertussis vaccine trials: results and impact on U.S. public health. Washington DC: National Institutes of Health; 1996.
43. Steele RW. Pertussis. Pediatr Infect Forum. 2002;4:3-13.
44. Christie CD, Garrison K, Kiely L, et al. Acellular pertussis vs. meningococcal vaccine trial in hospital workers during the Cincinnati pertussis epidemic. Clin Infect Dis. 1997;25:469.
45. Keitel WA. Cellular and acellular pertussis vaccines in adults. Clin Infect Dis. 1999;28(Suppl 2):S118-S123.
46. Keitel WA, Muenz LR, Decker MD, et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis. 1999;180(2):397-403.
47. Edwards KM, Decker MD, Graham BS, et al. Adult immunization with acellular pertussis vaccine. JAMA. 1993;269(1):53-56.
48. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics. 1997;100(5):772-788.
49. National Advisory Committee on Immunization. Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003;29:1-9.
50. Edwards KM. Pertussis: an important target for maternal immunization. Vaccine. 2003;21(24):3483-3486.